Hmga2 supports cancer hallmarks in triple-negative breast cancer

Behzad Mansoori, Mikkel Green Terp, Ali Mohammadi, Christina Bøg Pedersen, Henrik Jørn Ditzel, Behzad Baradaran, Morten Frier Gjerstorff*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

42 Downloads (Pure)


Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that exhibits a high proliferation rate and early metastasis leading to a poor prognosis. HMGA2 is a DNA binding transcriptional regulator implicated in tumorigenesis. Here, we demonstrate that the HMGA2 promoter is demethylated in TNBC tumors, leading to increased expression of HMGA2 at both mRNA and protein levels. Importantly, high HMGA2 levels in TNBC tumors are correlated with poor prognosis. To detail the role of HMGA2 in TNBC development and progression, we studied its effect on core cancer phenotypes. Stable knockdown of HMGA2 in TNBC cells revealed that HMGA2 may support cell proliferation, cell migration and invasion. In addition, HMGA2 knockdown decreased cancer stem cell (CSC) features. Importantly, we found that silencing HMGA2 inhibited NF-kB signaling and lead to decreased expression of the downstream molecules IL-6 and IL-8 and reduced STAT3 pathway activation. Our results demonstrate that HMGA2 supports cancer hallmarks in TNBC and may represent a promising target for TNBC treatment.

Original languageEnglish
Article number5197
Issue number20
Number of pages17
Publication statusPublished - 1. Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


  • HMGA2
  • IL-6
  • IL-8
  • NF-kB
  • STAT3
  • Triple-negative breast cancer


Dive into the research topics of 'Hmga2 supports cancer hallmarks in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this